Skip to main content
ProNeurogen logo

ProNeurogen

Tucson, Arizona, United StatesSee on the mapFounded 2013

ProNeurogen is a biotechnology company developing peptide-based therapies to slow vascular dementia and help preserve cognitive function. Its Mas receptor agonist platform is designed to reduce neuroinflammation and support brain blood flow, with programs spanning neurovascular, neurodegenerative, and neuroinflammatory conditions.

Raised
$50M
Investors
3
Founded
2013
Employees
2–10

reccy insights

Recent highlights

ProNeurogen’s public profile centers on its Mas receptor agonist programs and a focus on cognitive impairment and vascular dementia. Its technology lineup includes PNA5, a glycosylated Angiotensin-(1-7) peptide, and PNA1, another Mas receptor agonist associated with human studies in traumatic brain injury and post-operative cognitive impairment. The available funding history includes a $4,008,872 grant in September 2019 and a $1,211,531 grant in August 2020, both listing HHS as a lead investor. Further grant activity includes $4,973,914 in September 2022 and $7,608,242 on September 18, 2023. These are historical milestones rather than newly announced developments. The company’s stated intellectual-property position includes five patent families covering Mas receptor analog compositions, formulations, and therapeutic uses, under an exclusive University of Arizona license.

Written by reccy's AI from company sites, press and funding records · updated Nov 2026

What makes ProNeurogen distinct

  1. 01Focuses on therapies intended to slow vascular dementia and preserve cognitive function.
  2. 02Develops glycosylated Angiotensin-(1-7) peptides designed to selectively activate the Mas receptor.
  3. 03Targets inflammation and oxidative stress while aiming to support brain blood flow.
  4. 04Mas receptor biology supports potential applications across neurovascular, neurodegenerative, and neuroinflammatory disorders.
  5. 05Five patent families cover Mas receptor analog compositions, formulations, and therapeutic uses under an exclusive University of Arizona license.

Technology & products2

  • PNA5

    A glycosylated Angiotensin-(1-7) peptide and selective Mas receptor agonist being developed for vascular dementia and cognitive-function preservation.

  • PNA1

    A Mas receptor agonist associated with human studies in traumatic brain injury and post-operative cognitive impairment.

  • PNA5, a glycosylated Angiotensin-(1-7) peptide and selective Mas receptor agonist.
  • PNA1, a Mas receptor agonist associated with human studies in traumatic brain injury and post-operative cognitive impairment.
  • A Mas receptor agonist platform for neuroprotection and cognitive function.

Research roots1

Labs and research groups this company came from or works with.

  • University of ArizonaTucson, United States · No page yet
    Other link
Academic data: Carter Sciences

Recent updates2

  • Aug 2026Award

    August 2026 — NIH/NIA Awards $9 Million to Advance PNA5 into First-in-Human Clinical Testing

    proneurogen.com
  • Aug 2026Award

    NIH/NIA Awards $9 Million to Advance PNA5 into First-in-Human Clinical Testing

    proneurogen.com

Funding

$50M disclosed
  • Grant (prize money)Sep 2023
    $7.6M
  • Federal GrantSep 2023
    $500K
  • Grant (prize money)Sep 2022
    $5MLed by HHS
Latest valuation $9,967,0593 investors

Investors1

On reccy

About ProNeurogen

Products
PNA5, PNA1
Leadership
Meredith Hay
Focus areas
NeuroTechnology, biotech, therapeutics, pharmaceuticals, peptide therapeutics, vascular dementia, neuroscience, neuroinflammation
Headquarters
Tucson, Arizona, United States
Founded
2013
Employees
2–10
Status
Active · private